Close Menu

The Wall Street Journal has a commentary piece from Sidney Taurel, chairman and CEO of Eli Lilly and Company, on a recent flare-up over a drug candidate in clinical trials. The heart-attack drug, prasugrel, was in two trials that were halted pending review of a few cases of adverse effects. Taurel says the media coverage that followed this not only got the story wrong, but resulted in cutting Lilly's market cap by "about $6 billion."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.